EA
BBIO icon

Emerald Advisers’s BridgeBio Pharma BBIO Stock Holding History

Emerald Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-515,361
Closed -$38.3M – 241
2026
Q1 		$38.3M Sell
515,361
-20,403
-4% -$1.48M 1.21% 20
2025
Q4 		$41M Sell
535,764
-184,579
-26% -$12.1M 1.26% 19
2025
Q3 		$37.4M Sell
720,343
-300,914
-29% -$14.7M 1.2% 23
2025
Q2 		$44.1M Sell
1,021,257
-124,234
-11% -$4.52M 1.62% 11
2025
Q1 		$39.6M Sell
1,145,491
-5,377
-0.5% -$181K 1.78% 9
2024
Q4 		$31.6M Buy
1,150,868
+47,360
+4% +$1.22M 1.22% 25
2024
Q3 		$28.1M Buy
1,103,508
+437,164
+66% +$11.5M 1.09% 31
2024
Q2 		$16.9M Sell
666,344
-32,739
-5% -$895K 0.71% 55
2024
Q1 		$21.6M Buy
699,083
+13,544
+2% +$461K 0.87% 43
2023
Q4 		$27.7M Sell
685,539
-8,461
-1% -$254K 1.18% 21
2023
Q3 		$18.3M Buy
694,000
+214,875
+45% +$6.1M 0.89% 43
2023
Q2 		$8.24M Buy
+479,125
New +$7.21M 0.36% 97

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Emerald Advisers's BBIO Position: Q2 2026 in Review

Emerald Advisers sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 515,361 shares — an estimated $38.3M sold.

Emerald Advisers first reported a position in BBIO in Q2 2023 and held it in 12 quarters. The position peaked at $44.1M in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Emerald Advisers reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Emerald Advisers sold 515,361 BridgeBio Pharma shares in Q2 2026, an estimated $38.3M.
  • Emerald Advisers first reported a position in BridgeBio Pharma in Q2 2023 and held it in 12 quarters.
  • Emerald Advisers's BridgeBio Pharma position peaked at $44.1M in Q2 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.